Werewolf Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2024: 0.87%

Werewolf Therapeutics Inc (HOWL) has an Asset Resilience Ratio of 0.87% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check HOWL strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$1.22 Million

Cash + Short-term Investments

Total Assets

$140.04 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Werewolf Therapeutics Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Werewolf Therapeutics Inc to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Werewolf Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Werewolf Therapeutics Inc (HOWL) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$1.22 Million	0.87%
Total Liquid Assets	$1.22 Million	0.87%

Asset Resilience Insights

Limited Liquidity: Werewolf Therapeutics Inc maintains only 0.87% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Werewolf Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Werewolf Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Werewolf Therapeutics Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Werewolf Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Werewolf Therapeutics Inc

NASDAQ:HOWL USA Biotechnology

Market Cap

$16.72 Million

Market Cap Rank

#25706 Global

#5349 in USA

Share Price

$0.34

Change (1 day)

-4.44%

52-Week Range

$0.34 - $2.19

All Time High

$20.31